Related Experiment Videos
Long-term treatment outcome in acromegaly
I M Holdaway1, C R Rajasoorya, G D Gamble
1Department of Endocrinology, Auckland Hospital, Park Road, Auckland 1, New Zealand. ian@adhb.govt.nz
Summary
Defining biochemical remission in acromegaly is crucial for long-term outcomes. Current evidence suggests a random serum growth hormone (GH) level below 2.5 microg/L and normal insulin-like growth factor-I (IGF-I) indicate cure.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Oncology
Background:
- Acromegaly treatment aims for cure, but robust definitions of biochemical remission are lacking.
- Existing guidelines for acromegaly cure lack correlation with long-term patient outcomes.
- Current studies do not definitively establish biochemical remission criteria for acromegaly.
Purpose of the Study:
- To evaluate current definitions of biochemical remission in acromegaly.
- To correlate biochemical markers with long-term outcomes in treated acromegaly patients.
- To establish reliable criteria for defining acromegaly cure.
Main Methods:
- Review of available data and studies on acromegaly treatment outcomes.
- Analysis of serum growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels post-treatment.
- Correlation of biochemical markers with mortality and complication rates.
Main Results:
- Lowered random serum GH (<2.5 microg/L) or glucose-suppressed GH (<1 microg/L) may indicate mortality similar to the general population.
- Normalizing serum IGF-I significantly improves outcomes compared to elevated levels.
- A post-treatment random serum GH <2.5 microg/L combined with normal serum IGF-I defines biochemical cure.
Conclusions:
- Current evidence suggests a random serum GH <2.5 microg/L and normal serum IGF-I define biochemical cure in acromegaly.
- Achieving these biochemical targets reduces chronic complications and improves mortality.
- Further research with ultrasensitive assays may refine optimal GH levels for superior outcomes.